Literature DB >> 10023940

Thromboprophylaxis for atrial fibrillation.

G Y Lip1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10023940     DOI: 10.1016/S0140-6736(05)74877-7

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  6 in total

1.  Atrial fibrillation and antithrombotic treatment in Italian hospitalized patients: a prospective, observational study.

Authors:  W Ageno; F Ambrosini; B Nardo; D Imperiale; F Dentali; V Mera; R Cattaneo; E Barlocco; L Steidl; A Venco
Journal:  J Thromb Thrombolysis       Date:  2001-12       Impact factor: 2.300

Review 2.  Indobufen: an updated review of its use in the management of atherothrombosis.

Authors:  N Bhana; K J McClellan
Journal:  Drugs Aging       Date:  2001       Impact factor: 3.923

3.  The impact of patients' preferences on the treatment of atrial fibrillation: observational study of patient based decision analysis.

Authors:  J Protheroe; T Fahey; A A Montgomery; T J Peters
Journal:  BMJ       Date:  2000-05-20

4.  Effects of patients' preferences on the treatment of atrial fibrillation: observational study of patient-based decision analysis.

Authors:  J Protheroe; T Fahey; A A Montgomery; T J Peters
Journal:  West J Med       Date:  2001-05

5.  Primary prevention of arterial thromboembolism in non-rheumatic atrial fibrillation in primary care: randomised controlled trial comparing two intensities of coumarin with aspirin.

Authors:  B S Hellemons; M Langenberg; J Lodder; F Vermeer; H J Schouten; T Lemmens; J W van Ree; J A Knottnerus
Journal:  BMJ       Date:  1999-10-09

Review 6.  Should atrial fibrillation patients with hypertension as an additional risk factor of the CHA2DS2-VASc score receive oral anticoagulation?

Authors:  Juan Wang; Da-Peng Zhang; Hong-Bin Liu; Jiu-Chang Zhong; Xin-Chun Yang
Journal:  J Geriatr Cardiol       Date:  2018-03       Impact factor: 3.327

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.